Inhibikase Therapeutics, Inc. (IKT) company profile
Close on Nov 17, 2026Market cap $192.56MP/E –Yield –
About Inhibikase Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company that develops therapeutics designed to modify the course of cardiopulmonary diseases. The company focuses primarily on treatments for pulmonary arterial hypertension, an orphan disease marked by elevated pulmonary vascular resistance and vascular remodeling. Its primary product candidate is IKT-001, an oral prodrug of imatinib designed to minimize gastrointestinal adverse effects by exhibiting lower inhibitory activity at target tyrosine kinases such as c-Kit. As a clinical-stage entity, the company does not currently sell commercial products to end customers, but its pipeline targets patients suffering from pulmonary arterial hypertension.
The company's clinical operations include a two-part adaptive Phase 3 study known as IMPROVE-PAH, which spans approximately 180 planned clinical trial sites internationally. The company maintains principal executive offices located in Wilmington, Delaware. In addition, it operates corporate subsidiaries that include IKT Securities Corporation in Massachusetts and CorHepta Pharmaceuticals, Inc. in Delaware.
Summary of the business section of Inhibikase Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Inhibikase Therapeutics, Inc.
- Headquarters
- Wilmington, DE
- Address
- 1000 N. West Street, Suite 1200 19801
- Phone
- (302) 295-3800
- Website
- inhibikase.com
- Employees
- 35, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CohnReznick LLP, Holmdel, New Jersey
Stock & identifiers
- Ticker
- IKT
- Exchange
- Nasdaq
- IPO date
- Dec 28, 2020
- Shares outstanding
- 140M, Aug 4, 2026
- Public float
- $127.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-6 reverse, Jun 30, 2023
- SEC CIK
- 1750149
- CUSIP
- 45719W205
- ISIN
- US45719W2052
- FIGI
- BBG005TP2339
- Share class FIGI
- BBG005TP2348
- LEI
- 549300066CFEWOA17F12
- EIN
- 26-3407249
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mark T. Iwicki | Chief Executive Officer, Director | – |
| Milton H. Werner | President and CEO, Director | 5,359,022 |
| Christopher Cabell | President & Head of R&D | 676,564 |
| David McIntyre | Chief Financial Officer | 10,285 |
| Garth Lees-Rolfe | Chief Financial Officer | – |
| Scott M. Wasserman | Director | – |
| Dennis N. Berman | Director | 21,854 |
| David Canner | Director | – |
| Arvind Kush | Director | 145,000 |
| Vincent Aurentz | Director | 510,596 |
| Amit Munshi | Director | 403,176 |
| Roberto Bellini | Director | 1,460,000 |
| Roy Lester Freeman | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mark Iwicki | $30.59M | $29.68M | $6.50M | $161 | – |
| FY2025 Milton Werner | $803.06K | $735.63K | $6.50M | $161 | – |
| FY2024 | $7.98M | $7.60M | $790.28K | $256 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Mark Iwicki Chief Executive Officer and Director | $624.21K | $29.43M | $532.50K | – | $30.59M | – |
| Chris Cabell, M.D. President and Head of Research and Development | $429.17K | $6.76M | $281.25K | – | $7.48M | – |
| David McIntyre Chief Financial Officer | $347.22K | $4.90M | $272.81K | – | $5.52M | – |
| Milton H. Werner, Ph.D. Former President and Chief Executive Officer | $728.98K | $40.45K | $31.54K | $2.09K | $803.06K | -90% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 28, 2020
- Offer price
- $10.00
- Securities offered
- 1,800,000
- Gross proceeds
- $18.00M
- Exchange
- Nasdaq
- First trading day
- Dec 28, 2020
- First-day close
- $9.34-6.6%
- Lock-up ends (est.)
- Jun 26, 2021
“The initial public offering price of our shares is $10.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of the date of this Annual Report, we had thirty-five full time employees and no part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 26, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 24, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 29, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 28, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 29, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?